PEN · NYSE
Average $375.09 (+15.6% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Evercore ISI Group | Jul 6, 2026 | Maintains | Outperform |
| RBC Capital | Jun 11, 2026 | Maintains | Sector Perform |
| Citigroup | May 7, 2026 | Maintains | Neutral |
| Evercore ISI Group | May 7, 2026 | Maintains | Outperform |
| Evercore ISI Group | Feb 26, 2026 | Maintains | Outperform |
| RBC Capital | Jan 20, 2026 | Downgrade | Outperform → Sector Perform |
| Canaccord Genuity | Jan 20, 2026 | Downgrade | Buy → Hold |
| Jefferies | Jan 16, 2026 | Downgrade | Buy → Hold |
| Needham | Jan 16, 2026 | Downgrade | Buy → Hold |
| Citigroup | Jan 16, 2026 | Downgrade | Buy → Neutral |
Updated Jul 7, 2026
Penumbra is well positioned for growth due to its innovative technologies in the acute care setting and expanding global market. With the recent acquisition by Boston Scientific at a premium price of $374 per share, it is evident that Penumbra is a market leader with strong revenue growth potential and a profitable business. Risks include potential competition from larger medical technology companies and unexpected liabilities or investigations.
Penumbra is facing strong competition within the neurovascular market from competitors with significantly greater resources, such as Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo. These companies offer similar products and have more resources to potentially compete with Penumbra in terms of pricing, innovation, and market reach, which could lead to a decline in sales and market share for Penumbra. Additionally, potential changes in reimbursement for neurovascular procedures could negatively impact Penumbra's business. Despite the company's commitment to creating innovative products and promoting diversity, they have not tied sustainability goals to executive compensation, which may indicate a lack of long-term strategic planning.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
